22 June 2021>: Original Paper
Shift in Living Kidney Donor Demographics Over the Past 50 Years in a German Transplant Center
Claudia Sommerer 1ACDEF* , Zoi Bougioukou 1BCDEF , Vasileios L. Georgiou 2CD , Arianeb Mehrabi 3E , Martin Zeier 1EDOI: 10.12659/AOT.929693
Ann Transplant 2021; 26:e929693
Table 4 Renal function and outcome data of living kidney donors from 1967 to 2016.
Number of valid values (%760) | All1967–2016N=760 | 1967–1990N=51 | 1991–2000N=103 | 2001–2010N=342 | 2011–2016N=264 | p | |
---|---|---|---|---|---|---|---|
Time after donation (months), mean (SD) | 606 (79.7) | 105.5 (76.6) | 379.2 (68.0) | 239.7 (43.9) | 112.1 (34.2) | 47.4 (20.6) | |
Age (years), mean (SD) | 604 (79.4) | 59.3 (11) | 65.3 (7.8) | 66.4 (9.2) | 59.2 (11.5) | 57.1 (10.2) | |
External follow-up, n (%) | 611 (80.4) | 214 (35) | 10 (66.7) | 47 (65.3) | 124 (44.3) | 33 (13.5) | |
Creatinine (mg/dL), mean (SD), time of discharge | 646 (85) | 1.20 (0.28) | No valid values | 1.22 (0.20) | 1.20 (0.26) | 1.26 (0.30) | 0.833 |
CKDepi eGFR (mL/min/1.73m), mean (SD), time of discharge | 646 (85) | 60.5 (15.7) | No valid values | 61.5 (16.0) | 61.5 (15.2) | 59.5 (15.6) | 0.313 |
MDRD eGFR (mL/min/1.73 m), mean (SD), time of discharge | 646 (85) | 55.2 (14.2) | No valid values | 55.2 (13) | 56 (15.0) | 54.2 (13.5) | 0.482 |
Creatinine (mg/dL), mean (SD), year 1 | 532 (70) | 1.13 (0.25) | No valid values | 1.11 (0.21) | 1.13 (0.24) | 1.15 (0.25) | 0.755 |
CKDepi eGFR (mL/min/1.73 m), mean (SD), year 1 | 532 (70) | 65.2 (14.9) | No valid values | 68.8 (11.7) | 65.6 (14.2) | 64.3 (14.9) | 0.595 |
MDRD eGFR (mL/min/1.73 m), mean (SD), year 1 | 532 (70) | 60.0 (12.3) | No valid values | 63.2 (18.1) | 60.2 (12.0) | 59.4 (12.7) | 0.635 |
Creatinine (mg/dL), mean (SD), last visit | 576 (75.8) | 1.06 (0.24) | 0.94 (0.16) | 0.99 (0.20) | 1.03 (0.24) | 1.11 (0.24) | |
CKDepi eGFR (mL/min/1.73 m), mean (SD), last visit | 568 (74.7) | 68.1 (16.9) | 70.4 (14.2) | 69.9 (16.3) | 69.6 (17.9) | 65.8 (15.6) | 0.005 |
MDRD eGFR (mL/min/1.73 m), mean (SD), last visit | 568 (74.7) | 67.6 (16.3) | 70.5 (13.4) | 71.5 (16.4) | 69.2 (17.9) | 64.6 (14.0) | 0.061 |
CKD stage 3, n (%)* | 568 (74.7) | 201 (35.4) | 1 (11.1) | 21 (35.0) | 87 (33.3) | 92 (38.7) | 0.271 |
CKD stage 4, n (%)** | 568 (74.7) | 2.0 (0.4) | 0 (0) | 0 (0) | 1 (0.4) | 1 (0.4) | – |
ESRD | 568 (74.7) | 0 | 0 | 0 | 0 | 0 | – |
Hemoglobin (g/dL), mean (SD) | 554 (72.8) | 14.1 (1.2) | 14.2 (0.9) | 13.8 (1.3) | 14.1 (1.3) | 14.2 (1.2) | 0.469 |
Glucose (fasting) mg/dL, mean (SD) | 517 (68) | 96 (18) | 88 (9) | 100 (22) | 94 (19) | 97 (16) | 0.027 |
HbA1c ≥6.5%, n (%) | 517 (68) | 13 (2.5) | 0 (0) | 4 (8.2) | 5 (1.2) | 4 (2.7) | 0.065 |
HbA1c%, mean (SD) | 517 (68) | 5.59 (0.42) | 5.58 (0.3) | 5.79 (0.46) | 5.60 (0.4) | 5.53 (0.42) | 0.001 |
De novo hypertension, n (%) | 545 (71.7) | 124 (22.7) | 3 (60.0) | 26 (59.1) | 62 (33.0) | 33 (22.6) | a |
De novo diabetes mellitus, n (%) | 478 (62.8) | 11 (2.3) | 0 (0.0) | 3 (7.9) | 4 (1.9) | 4 (1.8) | 0.0932b |
Cardiovascular events, n (%) | 523 (69) | 47 (9) | 4 (40) | 13 (21.7) | 20 (8.9) | 10 (4.4) | 0.00 |
Malignancy, n (%) | 521 (69) | 33 (6.3) | 1 (10) | 7 (11.9) | 14 (6.3) | 11 (4.8) | 0.246 |
Donor deaths, n (%) | 644 (84.7) | 22 (2.9) | 4 (7.8) | 6 (5.8) | 10 (2.9) | 2 (0.8) | 0.00 |
CKD – chronic kidney disease; CKDepi – Chronic Kidney Disease Epidemiology Collaboration; eGFR – estimated glomerular filtration rate; ESRD – end-stage renal disease; MDRD – Modification of Diet in Renal Disease; n – number; p – significance; SD – standard deviation. * CKD stage 3, CKDepi eGFR=30–60 mL/min/1.73 m; ** CKD stage 4, CKDepi eGFR=15–30 mL/min/1.73 m. a Post-hoc comparison of percentages between periods (de novo hypertension): 1991–2000 vs 2001–2010: p=0.0071; 1991–2000 vs 2011–2016: p In the above post-hoc analysis, the Bonferroni correction was applied. b Post-hoc analysis is not needed for de novo diabetes mellitus since p=0.0932 (>0.05) but is helpful for hypertension since p |